Development Program

Acute Kidney Injury (AKI) to
Chronic Kidney Disease (CKD)
Transition

Aim

Identify novel compounds for treatment of patients with acute kidney injury (AKI) to prevent development of chronic kidney disease (CKD).

Brief description

Worldwide, in 2017, the total number of individuals with chronic kidney disease (CKD), acute kidney injury (AKI), and those receiving renal replacement therapy (RRT) exceeded 850 million. Mortality from CKD is increasing faster than mortality for most other causes and is expected to become the fifth global cause of death by 2040. Patients with AKI have a 9-fold increased risk of developing CKD. There is a clear medical need to develop novel treatment options to prevent AKI and/or to treat AKI to prevent AKI-to CKD transition.

Funding agency: European Union – MSCA training network
Status: Ongoing
Timeline: 2024 – 2028

Outcome / Opportunities

PICKED consortium partners

Get Involved

Learn how you can contribute to the exciting work happening at Delta4

Careers

Forging the innovative treatments of the future requires brilliant minds and we’re always on the lookout for talent.

Investors

Contact us to find out more about how you can invest with us and be a part of pioneering the next successful treatment.

Medical Community

Learn how you can partner with us and combine our technology with your knowledge to develop treatments faster.